Notably, the two cases of M-CLL developing RT after targeted therapies carried the IGLV3–21R110 mutation, which triggers cell-autonomous BCR signaling27 (Fig. 1c). This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.